TNFRSF11A and osteoporosis: A total of 153 patients (68.0%) were receiving osteoporosis treatment (Bisphosphonates/Active vitamin D/Calcium/Selective estrogen receptor modulator/Anti-receptor activator of nuclear factor kappa B ligand antibody/Sclerostin antibody: 44/106/45/26/39/5).